Review
Romatolojik ve otoimmün hastalıklarda interlökin 23/tip 17 yardımcı T hücreleri yolağı için etkili güncel tedavi yöntemleri
Abstract
İnterlökin 23/tip 17 yardımcı T hücreleri yolağı birçok otoimmün ve romatolojik hastalığın mekanizmasında rol oynar. Bu yolaktaki reseptörlerin ve sitokinlerin bloke edilerek inflamasyonun baskılanması, yeni terapötik ajanlar geliştirilmesi için ana hedef haline gelmiştir. Bu terapötik ajanlarla ilgili çalışmalar umut vericidir.
References
- 1. Bystrom J, Clanchy FIL, Taher TE, Al-Bogami M, Ong VH, Abraham DJ, et al. Functional and phenotypic heterogeneity of Th17 cells in health and disease. Eur J Clin Invest 2019;49:13032. 2. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis 2018;77:175-87. 3. Campa M et al. A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis. Dermatol Ther (Heidelb) 2016;6:1-12. 4. Gizinski AM, Fox DA. Emerging therapeutic targets: GM-CSF, IL-17, and IL-23. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 5th ed. Philadelphia: Mosby, Elsevier; 2015. p. 518-21. 5. Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 2013;34:174-81. 6. Gülbezer EE, Keser G.Biyolojik tedaviler. RAED Dergisi 2017;9(1-2):11-31. 7. McGinley AM, Edwards SC, Raverdeau M, Mills KHG. Th17 cells, g T cells and their interplay in EAE and multiple sclerosis. J Autoimmun 2018 Jan 21. pii: S0896-8411(18)30007-6. 8. Dong J, Goldenberg G. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors. Cutis 2017;99:123-127. 9. Cingoz O. Ustekinumab. MAbs 2009;1:216-21. 10. Koç E. Ustekinumab. Türkderm-Deri Hastalıkları ve Frengi Arivi Dergisi 2016;50(Suppl 1):435. 11. Traczewski P, Rudnicka L. Briakinumab for the treatment of plaque psoriasis. BioDrugs 2012;26:9-20. 12. Schurich A, Raine C, Morris V, Ciurtin C. The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade. Rheumatology (Oxford) 2018;57:246-54. 13. Geng W, Zhao J, Fu J, Zhang H, Qiao S. Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis. Exp Ther Med 2018;16:5085-95. 14. Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Targeting IL-23 in psoriasis: current perspectives. Psoriasis (Auckl) 2018;8:1-5. 15. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol 2017;140:645-53. 16. Kopp T, Riedl E, Bangert C, Bowman EP, Greisenegger E, Horowitz A, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 2015;521:222-6. 17. Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 2017;390:276-288. 18. Wechter T, Cline A, Feldman SR. Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab. Ther Clin Risk Manag 2018;14:1489-97. 19. Gottlieb A, Deodhar A, Boehncke WH. Efficacy and safety results of guselkumab, an anti-IL23 monoclonal antibody, in patients with active psoriatic arthritis: A Phase 2a, randomized, doubleblind, placebo-controlled study. J Am Acad Dermatol 2017;76(Suppl 1):AB111. 20. Haugh IM, Preston AK, Kivelevitch DN, Menter AM. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Devel Ther 2018;12:3879-83. 21. Gooderham MJ, Papp KA, Lynde CW. Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol 2018;32:1111-9. 22. Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis 2018;9:5-21. 23. Atakan N. Sekukinumab. Türkderm-Deri Hastalıkları ve Frengi Arivi Dergisi 2016;50(Suppl 1):46-7. 24. Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013;72:116-23. 25. Wu D, Yue J, Tam LS. Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis. Rheumatology (Oxford) 2018;57:563-71. 26. Megna M, Gallo L, Balato N, Balato A. A case of erythrodermic psoriasis successfully treated with ixekizumab. Dermatol Ther 2019 Jan 16:e12825. 27. Puig L. Brodalumab: the first anti-IL-17 receptor agent for psoriasis. Drugs Today (Barc) 2017;53:283-97.
Year 2018,
Volume: 3 Issue: 1-2, 25 - 30, 04.04.2019
Abstract
References
- 1. Bystrom J, Clanchy FIL, Taher TE, Al-Bogami M, Ong VH, Abraham DJ, et al. Functional and phenotypic heterogeneity of Th17 cells in health and disease. Eur J Clin Invest 2019;49:13032. 2. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis 2018;77:175-87. 3. Campa M et al. A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis. Dermatol Ther (Heidelb) 2016;6:1-12. 4. Gizinski AM, Fox DA. Emerging therapeutic targets: GM-CSF, IL-17, and IL-23. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 5th ed. Philadelphia: Mosby, Elsevier; 2015. p. 518-21. 5. Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 2013;34:174-81. 6. Gülbezer EE, Keser G.Biyolojik tedaviler. RAED Dergisi 2017;9(1-2):11-31. 7. McGinley AM, Edwards SC, Raverdeau M, Mills KHG. Th17 cells, g T cells and their interplay in EAE and multiple sclerosis. J Autoimmun 2018 Jan 21. pii: S0896-8411(18)30007-6. 8. Dong J, Goldenberg G. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors. Cutis 2017;99:123-127. 9. Cingoz O. Ustekinumab. MAbs 2009;1:216-21. 10. Koç E. Ustekinumab. Türkderm-Deri Hastalıkları ve Frengi Arivi Dergisi 2016;50(Suppl 1):435. 11. Traczewski P, Rudnicka L. Briakinumab for the treatment of plaque psoriasis. BioDrugs 2012;26:9-20. 12. Schurich A, Raine C, Morris V, Ciurtin C. The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade. Rheumatology (Oxford) 2018;57:246-54. 13. Geng W, Zhao J, Fu J, Zhang H, Qiao S. Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis. Exp Ther Med 2018;16:5085-95. 14. Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Targeting IL-23 in psoriasis: current perspectives. Psoriasis (Auckl) 2018;8:1-5. 15. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol 2017;140:645-53. 16. Kopp T, Riedl E, Bangert C, Bowman EP, Greisenegger E, Horowitz A, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 2015;521:222-6. 17. Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 2017;390:276-288. 18. Wechter T, Cline A, Feldman SR. Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab. Ther Clin Risk Manag 2018;14:1489-97. 19. Gottlieb A, Deodhar A, Boehncke WH. Efficacy and safety results of guselkumab, an anti-IL23 monoclonal antibody, in patients with active psoriatic arthritis: A Phase 2a, randomized, doubleblind, placebo-controlled study. J Am Acad Dermatol 2017;76(Suppl 1):AB111. 20. Haugh IM, Preston AK, Kivelevitch DN, Menter AM. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Devel Ther 2018;12:3879-83. 21. Gooderham MJ, Papp KA, Lynde CW. Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol 2018;32:1111-9. 22. Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis 2018;9:5-21. 23. Atakan N. Sekukinumab. Türkderm-Deri Hastalıkları ve Frengi Arivi Dergisi 2016;50(Suppl 1):46-7. 24. Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013;72:116-23. 25. Wu D, Yue J, Tam LS. Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis. Rheumatology (Oxford) 2018;57:563-71. 26. Megna M, Gallo L, Balato N, Balato A. A case of erythrodermic psoriasis successfully treated with ixekizumab. Dermatol Ther 2019 Jan 16:e12825. 27. Puig L. Brodalumab: the first anti-IL-17 receptor agent for psoriasis. Drugs Today (Barc) 2017;53:283-97.
There are 1 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Derleme |
| Authors | |
| Publication Date | April 4, 2019 |
| Published in Issue | Year 2018 Volume: 3 Issue: 1-2 |
